At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
AZD4635 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)
In Brief
A Phase 2 clinical trial evaluating AZD4635, Durvalumab, and 1 other intervention for Progressive Metastatic Castrate-Resistant Prostate Cancer. Completed, enrolled 30 participants across 16 sites in 5 countries.
Detailed Summary
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, South Korea, Spain, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionNov 2021
Study CompletionAug 2022
TodayJul 2026
First PostedJul 31, 2020
Enrollment StartAug 4, 2020
Primary CompletionNov 1, 2021
Study CompletionAug 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.9 years ago
Interventions
AZD4635drug
Subjects will receive AZD4635 orally daily
Durvalumabdrug
Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
Cabazitaxeldrug
Subjects will receive intravenous cabazitaxel every 3 weeks